Extended indication Chronic rhinosinusitis (CRS) patients who have had a prior functional endoscopic sinus surgery.
Therapeutic value No estimate possible yet
Registration phase Clinical trials

Product

Active substance Mometasone furoate sinus drug depot
Domain Lung diseases
Reason of inclusion New medicine (specialité)
Main indication Lung diseases other
Extended indication Chronic rhinosinusitis (CRS) patients who have had a prior functional endoscopic sinus surgery.
Manufacturer Intas
Mechanism of action Unknown
Route of administration Nasal
Therapeutical formulation Unknown
Budgetting framework Intermural (MSZ)
Additional remarks Werkingsmechaninsme: Glucocorticoid receptor agonist

Registration

Registration route Centralised (EMA)
Type of trajectory Unknown
Particularity Unknown
ATMP No
Submission date September 2024
Expected Registration October 2025
Orphan drug Unknown
Registration phase Clinical trials
Additional remarks NCT05219968

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

Dosage per administration 7500 µg

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

References https://richtlijnen.nhg.org/standaarden/acute-rhinosinusitis#:~:text=De%20incidentie%20van%20rhinosinusitis%20(zowel,vaker%20voor%20dan%20bij%20mannen.
Additional remarks De incidentie van rhinosinusitis (zowel acuut als chronisch) in de huisartsenpraktijk wordt geschat op 30 per 1.000 patiënten per jaar.

Expected cost per patient per year

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information